Renal iron overload in rats with diabetic nephropathy

Physiological Reports

Volumn 3, Issue 12, 2015, Pages

  Dominguez, Jesus H ^a,b   Liu, Yunlong ^a   Kelly, Katherine J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic; Complement; Diabetic nephropathies; Ischemia; Kidney failure

Indexed keywords

CATALASE; FERRITIN; GLUTATHIONE; IRON; LACTATE DEHYDROGENASE; OLEIC ACID; PALMITIC ACID; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; GENE ACTIVATION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IRON BINDING CAPACITY; IRON OVERLOAD; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE CELL; LEUKOCYTE; LIVER DISEASE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RNA SEQUENCE; SHAM PROCEDURE; WESTERN BLOTTING; ZUCKER FATTY RAT; ZUCKER LEAN RAT;

EID: 85005976093     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12654     Document Type: Article

References (43)

1. Babitt, J. L., F. W. Huang, D. M. Wrighting, Y. Xia, Y. Sidis, T. A. Samad, et al. 2006. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38:531–539.
2. Babitt, J. L., F. W. Huang, Y. Xia, Y. Sidis, N. C. Andrews, and H. Y. Lin. 2007. Modulation of bone morphogenic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest. 117:1933–1939.
3. Breyer, M. D., E. Bottinger, F. C. Brosius, T. M. Coffman, A. Fogo, R. C. Harris, et al. 2005. Diabetic nephropathy: of mice and men. Adv. Chronic Kidney Dis. 12:128–145.
4. Cohen, L. A., L. Gutierrez, A. Weiss, Y. Leichtmann-Bardoogo, D. L. Zhang, D. R. Crooks, et al. 2010. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116:1574–1584.
5. Dominguez, J., P. Wu, C. S. Packer, C. Temm, and K. J. Kelly. 2007. Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy. Am. J. Physiol. Renal. Physiol. 293:F670–F679.
6. Dominguez, J. H., J. L. Mehta, D. Li, P. Wu, K. J. Kelly, C. S. Packer, et al. 2008. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. Am. J. Physiol. 294:F110–F119.
7. Evstatiev, R., and C. Gasche. 2012. Iron sensing and signaling. Gut 61:933–952.
8. Gkouvatsos, K., C. Fillebeen, A. Daba, J. Wagner, G. Sebastiani, and K. Pantopoulos. 2014. Iron-dependent regulation of hepcidin in Hjv-/- mice: evidence that hemojuvelin is dispensable for sensing body iron levels. PLoS ONE 9:e85530.
9. Gulec, S., G. J. Anderson, and J. F. Collins. 2014. Mechanistic and regulatory aspects of intestinal iron absorption. Am. J. Physiol. 307:G397–G09.
10. Homer, N., B. Merriman, and S. F. Nelson. 2009. BFAST: an alignment tool for large scale genome resequencing. PLoS ONE 4:e7767.
11. Howard, R. L., B. Buddington, and A. C. Alfrey. 1991. Urinary albumin, transferrin, and iron excretion in diabetic patients. Kidney Int. 40:923–926.
12. Ishii, T., and G. E. Mann. 2014. Redox status in mammalian cells and stem cells during culture in vitro: critical roles of Nrf2 and cysteine transporter activity in the maintenance of redox balance. Redox. Biol. 2:786–794.
13. Kang, H. M., S. H. Ahn, P. Choi, Y. A. Ko, S. H. Han, F. Chinga, et al. 2015. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21:37–46.
14. Kartikasari, A. E., F. A. Wagener, A. Yachie, E. T. Wiegerinck, E. H. Kemna, and D. W. Swinkels. 2009. Hepcidin suppression and defective iron recycling account for dysregulation of iron homeostasis in heme oxygenase-1 deficiency. J. Cell Mol. Med. 13:3091–02.
15. Ten Kate, J., A. Wolthuis, B. Westerhuis, and C. van Deursen. 1997. The iron content of serum ferritin: physiological importance and diagnostic value. Eur. J. Clin. Chem. Clin. Biochem. 35:53–56.
16. Kelly, K. J., and J. H. Dominguez. 2010. Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am. J. Nephrol. 32:469–475.
17. Kelly, K. J., J. L. Burford, and J. H. Dominguez. 2009. The post-ischemic inflammatory syndrome: a critical mechanism of progression in diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 297:F923–F931.
18. Kelly, K. J., Y. Liu, J. Zhang, C. Goswami, H. Lin, and J. H. Dominguez. 2013. Comprehensive genomic profiling in diabetic nephropathy reveals the predominance of proinflammatory pathways. Physiol. Genomics 45:710–719.
19. Kelly, K. J., Y. Liu, J. Zhang, and J. H. Dominguez. 2015. Renal C3 component of complement; fast forward to diabetic kidney disease. Am. J. Nephrol. 41:48–56.
20. Khan, A. A., and J. G. Quigley. 2013. Heme and FLVCRrelated transporter families SLC48 and SLC49. Mol. Aspects Med. 34:669–682.
21. Kusminski, C. M., W. L. Holland, K. Sun, J. Park, S. B. Spurgin, Y. Lin, et al. 2012. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat. Med. 18:1539–1549.
22. Latour, C., L. Kautz, C. Besson-Fournier, M. L. Island, F. Canonne-Hergaux, O. Loreal, et al. 2014. Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and suppression of hepcidin. Hepatology 59:683–694.
23. Liu, R. M., and K. A. Gaston Pravia. 2010. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radic. Biol. Med. 48:1–15.
24. Madsen, M., J. H. Graversen, and S. K. Moestrup. 2001. Haptoglobin and CD163: captor and receptor gating hemoglobin to macrophage lysosomes. Redox Rep. 6:386–388.
25. McDonald, C. J., D. F. Wallace, L. Ostini, and V. N. Subramaniam. 2014. Parenteral vs. oral iron: influence on hepcidin signaling pathways though analysis of Hfe/Tfr2- null mice. Am. J. Physiol. Gastrointest. Liver Physiol. 306: G132–G139.
26. Mortazavi, A., B. A. Williams, K. McCue, L. Schaeffer, and B. Wold. 2008. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5:621–628.
27. Nakhoul, F. M., R. Miller-Lotan, H. Awad, R. Asleh, K. Jad, N. Nakhoul, et al. 2009. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. Am. J. Physiol. Renal. Physiol. 296:F830–F08.
28. Nam, S. Y., and K. Sabapathy. 2011. p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1. Oncogene 30:4476–4486.
29. Neau, D. B., G. Bender, W. E. Boeglin, S. G. Bartlett, A. R. Brash, and M. E. Newcomer. 2014. Crystal structure of a lipoxygenase in complex with substrate: the arachidonic acid-binding site of 8R-lipoxygenase. J. Biol. Chem. 289:31905–31913.
30. Paller, M. S., and B. E. Hedlund. 1988. Role of iron in postischemic renal injury in the rat. Kidney Int. 34:474–480.
31. Papanikolaou, G., and K. Pantopoulos. 2005. Iron metabolism and toxicity. Toxicol. Appl. Pharmacol. 202:199–11.
32. Parrow, N. L., and R. E. Fleming. 2014. Bone morphogenic proteins as regulators of iron metabolism. Annu. Rev. Nutr. 34:77–94.
33. Percival, M. D. 1991. Human 5-lipoxygenase contains an essential iron. J. Biol. Chem. 266:10058–10061.
34. Rajpathak, S. N., J. P. Crandall, J. Wylie-Rosett, G. C. Kabat, T. E. Rohan, and F. B. Hu. 2009. The role of iron in type 2 diabetes in humans. Biochim. Biophys. Acta 1790:671–681.
35. Riemer, J., H. H. Hoepken, H. Czerwinska, S. R. Robinson, and R. Dringen. 2004. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal. Biochem. 331:370–375.
36. Shah, S. V., M. M. Rajapurkar, and R. Baliga. 2011. The role of catalytic iron in acute kidney injury. Clin. J. Am. Soc. Nephrol. 6:2329–2331.
37. Temm, C., and J. H. Dominguez. 2007. Microcirculation: nexus of comorbidities in diabetes. Am. J. Physiol. Renal. Physiol. 293:F486–F493.
38. U.S. Renal Data System. 2013. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
39. Valenti, L., R. Rametta, P. Dongiovanni, B. M. Motta, E. Canavesi, S. Pelusi, et al. 2012. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS ONE 7:e48804.
40. Vashchenko, G., and R. T. MacGillivray. 2013. Multicopper oxidases and human iron metabolism. Nutrients 5:2289–13.
41. de Vries, B., S. J. Walter, L. von Bonsdorff, T. G. Wolfs, L. W. van Heurn, J. Parkkinen, et al. 2004. Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury. Transplantation 77:669–675.
42. de Vries, B., M. G. Snoeijs, von Bonsdorff L., Ernest van Heurn L. W., J. Parkkinen, and W. A. Buurman. 2006. Redox-active iron released during machine perfusion predicts viability of ischemically injured deceased donor kidneys. Am. J. Transplant. 6:2686–2693.
43. Zheng, X., T. Jiang, H. Wu, D. Zhu, L. Wang, R. Qi, et al. 2011. Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis. Am. J. Clin. Nutr. 94:1012–1019